VYNE Therapeutics (VYNE) Net Cash Flow (2017 - 2026)
VYNE Therapeutics (VYNE) posted Net Cash Flow of $604000.0 for Q1 2026, up 109.75% on a QoQ basis from -$6.2 million in Q2 2025, and down 92.71% year-over-year from $8.3 million in Q1 2025.
VYNE Therapeutics (VYNE) Net Cash Flow (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Net Cash Flow history runs 10 years deep, the most recent figure standing at $604000.0 for Q1 2026.
- Quarterly Net Cash Flow fell 92.71% year-over-year to $604000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 70.42% YoY) and the FY2025 annual result came in at $4.1 million, up 138.16% from the prior year.
- Net Cash Flow was $604000.0 for Q1 2026 at VYNE Therapeutics, up from -$6.2 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $15.2 million in Q4 2023 and bottomed at -$13.3 million in Q3 2024.
- A 5-year average of -$1.3 million and a median of -$4.6 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow soared 429.68% — and 2024, when it slumped 1562.59%.
- VYNE Therapeutics' Net Cash Flow stood at -$4.6 million in 2022, then surged by 429.68% to $15.2 million in 2023, then slumped by 76.23% to $3.6 million in 2024, then slumped by 271.83% to -$6.2 million in 2025, then soared by 109.75% to $604000.0 in 2026.
- Business Quant data shows VYNE's Net Cash Flow at $604000.0 in Q1 2026, -$6.2 million in Q2 2025, and $8.3 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 224.46 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 57.19 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 604,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 604,000.00 |
| Mar 31, 2026 | 604,000.00 |
| Jun 30, 2025 | -6.20 Mn |
| Jun 30, 2025 | -6.20 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Dec 31, 2024 | 3.61 Mn |
| Dec 31, 2024 | 3.61 Mn |
| Sep 30, 2024 | -13.34 Mn |
| Sep 30, 2024 | -13.34 Mn |
| Jun 30, 2024 | 10.54 Mn |
| Jun 30, 2024 | 10.54 Mn |
| Mar 31, 2024 | -11.56 Mn |
| Mar 31, 2024 | -11.56 Mn |
| Dec 31, 2023 | 15.17 Mn |
| Dec 31, 2023 | 15.17 Mn |
| Sep 30, 2023 | -5.20 Mn |
| Sep 30, 2023 | -5.20 Mn |
| Jun 30, 2023 | -9.58 Mn |
| Jun 30, 2023 | -9.58 Mn |